心血管

订阅

MedSci主页 / 所有栏目 / 心血管

抗CD38抗体-药物偶联物（ADC）STI-6129治疗淀粉样变性：FDA已批准IND

2020-05-27 Allan MedSci原创

淀粉样变性STI-6129
关注

Sorrento制药公司今日宣布，美国FDA已批准STI-6129治疗淀粉样变性的研究性新药申请（IND）。

Sorrento制药公司今日宣布，美国FDA已批准STI-6129治疗淀粉样变性的研究性新药申请（IND）。STI-6129融合了多种技术：从G-MAB™抗体文库中鉴定出的全人源抗CD38特异性抗体及位点特异性C-LOCK偶联技术。

Sorrento Therapeutics董事长兼首席执行官Henry Ji博士说：“STI-6129将与我们的CD38 CAR-T计划一起，有望成为淀粉样变性患者的治疗选择。我们期待在临床试验中进一步评估STI-6129的安全性和有效性”。Sorrento打算在晚期复发和/或难治性全身性淀粉样变性患者中启动I期多中心、开放标签、剂量递增的临床试验，其主要目的是确定STI-6129的安全性、初步疗效和药代动力学特征。

淀粉样变性是一个通用术语，用来指由各种蛋白质的低分子量亚单位组成的原纤维在细胞外组织发生沉积，这些蛋白质大多作为血浆成分进行循环。这些沉积物可能会导致许多不同的临床表现，这取决于沉积物的类型、沉积部位和沉积量。

 

原始出处：

https://www.firstwordpharma.com/node/1727296?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-10-14 zhwj

    #STI-6129#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2021-01-13 lvygwyt2789

    #抗体-药物偶联物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 xjy03

    #淀粉样变#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 zhouqu_8

    #淀粉样变性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 huangdf

    #变性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2035962, encodeId=8ae6203596267, content=<a href='/topic/show?id=8f5e16801f0' target=_blank style='color:#2F92EE;'>#STI-6129#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16801, encryptionId=8f5e16801f0, topicName=STI-6129)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Oct 14 19:02:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646580, encodeId=3ac01646580cc, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Wed Jan 13 05:02:21 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405189, encodeId=0e4114051897a, content=<a href='/topic/show?id=cb6e6591850' target=_blank style='color:#2F92EE;'>#淀粉样变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65918, encryptionId=cb6e6591850, topicName=淀粉样变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ca02527521, createdName=xjy03, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434684, encodeId=6d1c1434684d6, content=<a href='/topic/show?id=940265920ab' target=_blank style='color:#2F92EE;'>#淀粉样变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65920, encryptionId=940265920ab, topicName=淀粉样变性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463717, encodeId=c4de1463e170f, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469164, encodeId=e1e91469164c5, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Fri May 29 08:02:21 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 xiaogang319

    #IND#

    0

相关资讯

JACC：心肌淀粉样变性患者直流电复律的预后研究

心律失常、传导异常和心脏内栓塞是心肌淀粉样变性（CA）的常见并发症，对伴心房心律失常CA患者进行直流电复律（DCCV）的预后尚不清楚。本研究的目的旨在评估CA患者接受DCCV的预后。本研究纳入了58例CA患者（平均年龄69 ± 9 岁，男性占81%），与对照患者相比，CA患者电复律取消的概率更大（28% vs. 7%； p < 0.001），主要由于心脏内血栓形成（81% vs. 25%；

JACC：PET可以预测心肌淀粉样变性患者的预后

目前，对于心肌淀粉样沉积程度的非侵入性评估是否能预测轻链（AL）心肌淀粉样变性患者的预后尚不清楚。本研究的目的旨在评估11C-PiB PET是否能预测AL心肌淀粉样变性的预后。本研究纳入分析了41名AL心肌淀粉样变性患者，主要终点事件是全因死亡、心脏移植和急性心衰的复合事件。分析结果显示，相比于对照，11C-PiB PET的摄入在心肌淀粉样变性患者中更高，并与免疫组化的淀粉沉积程度相符。在平均42

隐匿性气管淀粉样变性全身麻醉1例

气道管理是临床麻醉的焦点问题，但是因气管病变带来的气道狭窄往往具有隐匿性的特点，常在重度狭窄时才能出现明显的临床症状，在症状不典型时，往往难以预估，给麻醉诱导气管插管带来了难以预料的风险。本文介绍1例术前无明显呼吸道症状、未诊断气管狭窄全身麻醉诱导的处理和分析。

JACC：腕管综合征患者的心脏淀粉样改变

心脏淀粉样变性患者经常会在心脏表现出现之前出现腕管综合征。本研究的目的旨在评估接受腕管手术患者心肌淀粉样沉积的发生率和类型。本研究共纳入了98名腕管综合征患者（平均年龄68岁，男性占51%），其中10名患者由组织活检染色检出淀粉样变性，2名患者被诊断为遗传性甲状腺素运载蛋白淀粉样变性（ATTR），2名患者被检查出有心脏表现，3名患者开始了治疗。在这些由活检诊断的ATTR患者中，血清的甲状腺旁素水平

JACC：心肌水肿和淀粉样变性

轻链（AL）和甲状旁腺素（ATTR）淀粉样变患者的预后受心脏表现的影响。ATTR淀粉样变的预后优于AL淀粉样变，提示AL淀粉样变发表机制的不同。本研究的目的旨在评估淀粉样变性患者心肌水肿的发生率及其对预后的影响。本研究纳入了286名淀粉样变患者，其中100名为系统性AL淀粉样变，163名为心脏ATTR淀粉样变，12名为疑似心脏ATTR淀粉样变患者，11名为无症状的淀粉样TTR基因突变携带者，30名

PNAS：小分子可稳定淀粉样蛋白生成免疫球蛋白轻链

在Ig轻链（LC）淀粉样变性（AL）中，由每个患者中的单克隆浆细胞分泌的独特抗体LC蛋白错误折叠和/或聚集，这是导致器官变性的过程。

拓展阅读

眼眶淀粉样变性影像诊断

淀粉样变性(amyloidosis)是一类以淀粉样蛋白在组织中异常沉积为特征的疾病。眼眶淀粉样变性包括两种临床类型，分别是局灶性和系统性。

Rheumatology：强直性脊柱炎患者淀粉样变性的风险、预测因素和预后

强直性脊柱炎（AS）是一种炎症性风湿性疾病，代表SPA疾病组的终末表型。目前的基于人群的队列研究表明，AS使淀粉样变性的风险增加6倍。

NEJM：悬雍垂淀粉样变性-病例报道

淀粉样变性病的特征是异常蛋白沉积在细胞外组织中。在疾病的轻链形式中，细胞外组织源自与浆细胞相关的免疫球蛋白轻链。

病例报道|以腹水为首发表现的肝淀粉样变性

淀粉样变性为引起腹水的罕见病因，可累及多器官，临床表现多样，预后差，易被漏诊。本例患者以腹水为首发表现，经多学科协作诊治后，最终确诊为肝淀粉样变性所致的肝窦阻塞综合征。消化科医师应重视腹水罕见病因的诊

隐匿性气管淀粉样变性全身麻醉1例

气道管理是临床麻醉的焦点问题，但是因气管病变带来的气道狭窄往往具有隐匿性的特点，常在重度狭窄时才能出现明显的临床症状，在症状不典型时，往往难以预估，给麻醉诱导气管插管带来了难以预料的风险。本文介绍1例术前无明显呼吸道症状、未诊断气管狭窄全身麻醉诱导的处理和分析。

JACC：PET可以预测心肌淀粉样变性患者的预后

目前，对于心肌淀粉样沉积程度的非侵入性评估是否能预测轻链（AL）心肌淀粉样变性患者的预后尚不清楚。本研究的目的旨在评估11C-PiB PET是否能预测AL心肌淀粉样变性的预后。本研究纳入分析了41名AL心肌淀粉样变性患者，主要终点事件是全因死亡、心脏移植和急性心衰的复合事件。分析结果显示，相比于对照，11C-PiB PET的摄入在心肌淀粉样变性患者中更高，并与免疫组化的淀粉沉积程度相符。在平均42